Pharmacyte Biotech Stock Probability of Future Stock Price Finishing Under 1.81
| PMCB Stock | USD 1.67 0.08 4.57% |
PharmaCyte |
PharmaCyte Biotech Target Price Odds to finish below 1.81
The tendency of PharmaCyte Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under $ 1.81 after 90 days |
| 1.67 | 90 days | 1.81 | about 67.34 |
Based on a normal probability distribution, the odds of PharmaCyte Biotech to stay under $ 1.81 after 90 days from now is about 67.34 (This PharmaCyte Biotech probability density function shows the probability of PharmaCyte Stock to fall within a particular range of prices over 90 days) . Probability of PharmaCyte Biotech price to stay between its current price of $ 1.67 and $ 1.81 at the end of the 90-day period is about 46.86 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.02 indicating PharmaCyte Biotech market returns are sensitive to returns on the market. As the market goes up or down, PharmaCyte Biotech is expected to follow. Additionally PharmaCyte Biotech has an alpha of 0.1538, implying that it can generate a 0.15 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). PharmaCyte Biotech Price Density |
| Price |
Predictive Modules for PharmaCyte Biotech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as PharmaCyte Biotech. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of PharmaCyte Biotech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
PharmaCyte Biotech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. PharmaCyte Biotech is not an exception. The market had few large corrections towards the PharmaCyte Biotech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold PharmaCyte Biotech, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of PharmaCyte Biotech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.15 | |
β | Beta against Dow Jones | 1.02 | |
σ | Overall volatility | 0.11 | |
Ir | Information ratio | 0.03 |
PharmaCyte Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of PharmaCyte Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for PharmaCyte Biotech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| PharmaCyte Biotech had very high historical volatility over the last 90 days | |
| PharmaCyte Biotech may become a speculative penny stock | |
| PharmaCyte Biotech has high likelihood to experience some financial distress in the next 2 years | |
| PharmaCyte Biotech currently holds about 82.23 M in cash with (2.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| PharmaCyte Biotech has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Disposition of tradable shares by Schmieg Martin of PharmaCyte Biotech subject to Rule 16b-3 |
PharmaCyte Biotech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of PharmaCyte Stock often depends not only on the future outlook of the current and potential PharmaCyte Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. PharmaCyte Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 9.6 M | |
| Cash And Short Term Investments | 50.2 M |
PharmaCyte Biotech Technical Analysis
PharmaCyte Biotech's future price can be derived by breaking down and analyzing its technical indicators over time. PharmaCyte Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of PharmaCyte Biotech. In general, you should focus on analyzing PharmaCyte Stock price patterns and their correlations with different microeconomic environments and drivers.
PharmaCyte Biotech Predictive Forecast Models
PharmaCyte Biotech's time-series forecasting models is one of many PharmaCyte Biotech's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary PharmaCyte Biotech's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about PharmaCyte Biotech
Checking the ongoing alerts about PharmaCyte Biotech for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for PharmaCyte Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| PharmaCyte Biotech had very high historical volatility over the last 90 days | |
| PharmaCyte Biotech may become a speculative penny stock | |
| PharmaCyte Biotech has high likelihood to experience some financial distress in the next 2 years | |
| PharmaCyte Biotech currently holds about 82.23 M in cash with (2.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| PharmaCyte Biotech has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Disposition of tradable shares by Schmieg Martin of PharmaCyte Biotech subject to Rule 16b-3 |
Check out PharmaCyte Biotech Backtesting, PharmaCyte Biotech Valuation, PharmaCyte Biotech Correlation, PharmaCyte Biotech Hype Analysis, PharmaCyte Biotech Volatility, PharmaCyte Biotech History as well as PharmaCyte Biotech Performance. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. If investors know PharmaCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PharmaCyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.64 | Return On Assets (0.05) | Return On Equity 0.4788 |
The market value of PharmaCyte Biotech is measured differently than its book value, which is the value of PharmaCyte that is recorded on the company's balance sheet. Investors also form their own opinion of PharmaCyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is PharmaCyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PharmaCyte Biotech's market value can be influenced by many factors that don't directly affect PharmaCyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PharmaCyte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PharmaCyte Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PharmaCyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.